Your browser doesn't support javascript.
loading
Current Landscape of Gene Therapy for the Treatment of Cardiovascular Disorders.
Wal, Pranay; Aziz, Namra; Singh, Chetan Pratap; Rasheed, Azhar; Tyagi, Lalit Kumar; Agrawal, Ankur; Wal, Ankita.
Afiliación
  • Wal P; PSIT-Pranveer Singh Institute of Technology (Pharmacy), NH-19, Kanpur, Uttar Pradesh, 209305, India.
  • Aziz N; PSIT-Pranveer Singh Institute of Technology (Pharmacy), NH-19, Kanpur, Uttar Pradesh, 209305, India.
  • Singh CP; Department of Pharmacy, Servier India Private Limited, India.
  • Rasheed A; PSIT-Pranveer Singh Institute of Technology (Pharmacy), NH-19, Kanpur, Uttar Pradesh, 209305, India.
  • Tyagi LK; Department of Pharmacy, Lloyd Institute of Management and Technology, Plot No.-11, Knowledge Park-II, Greater Noida, Uttar Pradesh, 201306, India.
  • Agrawal A; School of Pharmacy, Jai Institute of Pharmaceutical Sciences and Research, Gwalior, MP, India.
  • Wal A; PSIT-Pranveer Singh Institute of Technology (Pharmacy), NH-19, Kanpur, Uttar Pradesh, 209305, India.
Curr Gene Ther ; 24(5): 356-376, 2024.
Article en En | MEDLINE | ID: mdl-38288826
ABSTRACT
Cardiovascular disorders (CVD) are the primary cause of death worldwide. Multiple factors have been accepted to cause cardiovascular diseases; among them, smoking, physical inactivity, unhealthy eating habits, age, and family history are flag-bearers. Individuals at risk of developing CVD are suggested to make drastic habitual changes as the primary intervention to prevent CVD; however, over time, the disease is bound to worsen. This is when secondary interventions come into play, including antihypertensive, anti-lipidemic, anti-anginal, and inotropic drugs. These drugs usually undergo surgical intervention in patients with a much higher risk of heart failure. These therapeutic agents increase the survival rate, decrease the severity of symptoms and the discomfort that comes with them, and increase the overall quality of life. However, most individuals succumb to this disease. None of these treatments address the molecular mechanism of the disease and hence are unable to halt the pathological worsening of the disease. Gene therapy offers a more efficient, potent, and important novel approach to counter the disease, as it has the potential to permanently eradicate the disease from the patients and even in the upcoming generations. However, this therapy is associated with significant risks and ethical considerations that pose noteworthy resistance. In this review, we discuss various methods of gene therapy for cardiovascular disorders and address the ethical conundrum surrounding it.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Terapia Genética Aspecto: Ethics / Patient_preference Límite: Animals / Humans Idioma: En Revista: Curr Gene Ther Asunto de la revista: GENETICA MEDICA / TERAPEUTICA Año: 2024 Tipo del documento: Article País de afiliación: India Pais de publicación: Emiratos Árabes Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Terapia Genética Aspecto: Ethics / Patient_preference Límite: Animals / Humans Idioma: En Revista: Curr Gene Ther Asunto de la revista: GENETICA MEDICA / TERAPEUTICA Año: 2024 Tipo del documento: Article País de afiliación: India Pais de publicación: Emiratos Árabes Unidos